Procedural results from the RIBS V trial presented

October 30, 2013

A clinical trial comparing the use of drug-eluting stents (DES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from bare metal stents found that both techniques yielded positive long term outcomes. Findings from the RIBS V trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Treatment of with in-stent restenosis (ISR) remains a challenge. Drug-eluting balloons (DEB) have demonstrated effectiveness in patients with (BMS) ISR. However, the relative value of DEB versus new generation DES has not been measured.

In RIBS V, patients presenting with BMS ISR (>50 percent diameter stenosis) and angina or objective evidence of ischemia were eligible. Patients with very diffuse ISR (>30 mm), total occlusions or ISR in small vessels (<2.0 mm) were excluded. Patients with short life expectancy and those with severe associated conditions precluding late angiography were also excluded.

The primary endpoint of the study was the comparison of minimal lumen diameter (MLD) at nine month follow-up between the two arms.

A total of 189 patients with BMS ISR were randomized at 25 Spanish University Hospitals. Of these, 95 were allocated to DEB and 94 to EES. Mean age was 66±11 years and 25 patients (13 percent) were female. Cross-over to DES was required in eight patients in the DEB arm. Late angiographic follow-up was obtained in 92 percent of eligible patients.

At follow up, MLD in segment (primary study endpoint) was 2.36 mm in the EES group and 2.01 mm in the DEB group. MLD in lesion was 2.44 mm in the EES group and 2.03 mm in the DEB group. These angiographic differences were statistically significant. However, restenosis rate (4.7 percent and 9.5 percent) and late loss were very low and similar in both groups.

"In patients with BMS-ISR both DEB and EES provide excellent long-term clinical outcomes with very low rate of clinical and angiographic recurrences," said lead investigator Fernando Alfonso, MD, PhD. Dr. Alfonso is Head of the Cardiac Department at the Hospital Universitario de la Princesa in Madrid, Spain.

"However, EES provide superior late angiographic results including MLD, the primary endpoint, and percent diameter stenosis. Further studies (larger and with longer follow-up) are required to elucidate if these superior late angiographic findings eventually translate into a clinical benefit."

Explore further: Results of the DEB-AMI Trial reported at TCT 2011

Related Stories

Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011

A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Results of the SORT-OUT VI trial presented

October 30, 2013

A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible ...

Results of the TRYTON trial presented

October 30, 2013

A clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal stent in true bifurcation coronary lesions found that that the strategy was safe, but the results did not establish ...

Six-month data of the LEVANT 2 trial presented

October 30, 2013

The first clinical trial in the United States to study the use of drug coated balloons (DCB) for femoropopliteal artery disease found the procedure is promising for safety and efficacy at six months. Six month data of the ...

Recommended for you

Researchers find sleep gene linked to heart failure

November 30, 2015

Researchers at the Stanford University School of Medicine have identified a gene that, when working properly, appears to reduce the risk of heart failure and improve treatment outcomes, highlighting a possible target for ...

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.